Clinical Trial Results:
Phase 1 of dose escalation of extracorporeal shockwave treatment only and in combination DPP-4 inhibitor and parathyroid hormone (non-randomised, open-labelled) & Phase II of combination treatments of shockwave, a DPP-4 inhibitor and parathyroid hormone (randomised-controlled, open-labelled) in the ischemic cardiomyopathy population.
Summary
|
|
EudraCT number |
2013-004333-33 |
Trial protocol |
GB |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Aug 2025
|
First version publication date |
07 Aug 2025
|
Other versions |
|
Summary report(s) |
SHOCK-HF_Notification-End-of-Clinical-Trial-Medicine |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.